MCM
LXRX icon

Moore Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Moore Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-21,429
Closed -$270K – 505
2013
Q4 		$270K Buy
+21,429
New +$341K ﹤0.01% 358

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Moore Capital Management's LXRX Position: Q1 2014 in Review

Moore Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2014, closing a stake of 21,429 shares — an estimated $270K sold.

Moore Capital Management first reported a position in LXRX in Q4 2013 and held it in 1 quarter. The position peaked at $270K in Q4 2013. 103 funds tracked by Wall St. Rank hold LXRX as of Q1 2014.

  • Moore Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Moore Capital Management sold 21,429 Lexicon Pharmaceuticals shares in Q1 2014, an estimated $270K.
  • Moore Capital Management first reported a position in Lexicon Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Moore Capital Management's Lexicon Pharmaceuticals position peaked at $270K in Q4 2013.
  • 103 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2014.

Based on Moore Capital Management's 13F filing for Q1 2014, filed 15 May 2014.